Skip to main content

Table 2 Quantitative and qualitative analysis of microglia density within the dorsal horn and thalamus after indicated time points of diabetes

From: Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain

Mouse Cohort

Microglial Density in Ventral Lumbar Spinal Cord (number/mm2)

 

1 Month

3 Months

5 Months

8 Months

Non-Diabetic

167.3 ± 14.9 (-)

154.1 ± 11.3 (-)

142.1 ± 15.8 (-)

139.2 ± 13.4 (-)

Diabetic

183.8 ± 16.7 (-)

227.5 ± 14.2* (+)

308.4 ± 19.6* (+)

256.4 ± 22.5* (+)

 

Microglial Density in Thalamic Nuclei (number/mm 2 )

 

1 Month

3 Months

5 Months

8 Months

Non-Diabetic

108.6 ± 10.2(-)

104.3 ± 9.8(-)

101.2 ± 9.6 (-)

99.5 ± 8.4 (-)

Diabetic

113.2 ± 12.4(-)

123.0 ± 11.4 (+/-)

128.3 ± 10.1* (+/-)

116.3 ± 13.7 (-/+)

  1. All measures are mean +/- SEM for microglial densities. * indicates significance at p < 0.05 with comparison of non-diabetic and diabetic mice cohort groups (non-matched ANOVA tests, F-values range between 1.08-13.9 for indicated groups and time points, DF ≥ 7,4, n ≥ 4 at each time point. Microglial activation is indicated using a qualitative scale: - for baseline staining; + for mild response; and ++ for moderate response, with the statistical mode response indicated in brackets, or where two values were similar, the greater response is shown in front of the second most common value.